Efficacy and safety of eptinezumab in a predominantly Asian population with chronic migraine: Results of the randomized, double-blind, placebo-controlled SUNRISE trial.
- DOI
- 10.1177/03331024251386095
- Published
- 2025 Oct
- Container
- Cephalalgia : an international journal of headache
- Publisher
- Not recorded
- Open access
- unknown
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1177/03331024251386095,
title = {Efficacy and safety of eptinezumab in a predominantly Asian population with chronic migraine: Results of the randomized, double-blind, placebo-controlled SUNRISE trial.},
author = {Yu S and Matsumori Y and Kim BK and Gryglas-Dworak A and Giorgadze G and Pozo-Rosich P and Krog Josiassen M and Ranc K and Ettrup A and Mittoux A and Sperling B and Takeshima T},
year = {2025},
journal = {Cephalalgia : an international journal of headache},
doi = {10.1177/03331024251386095},
url = {https://doi.org/10.1177/03331024251386095}
}RIS
TY - JOUR TI - Efficacy and safety of eptinezumab in a predominantly Asian population with chronic migraine: Results of the randomized, double-blind, placebo-controlled SUNRISE trial. AU - Yu S AU - Matsumori Y AU - Kim BK AU - Gryglas-Dworak A AU - Giorgadze G AU - Pozo-Rosich P AU - Krog Josiassen M AU - Ranc K AU - Ettrup A AU - Mittoux A AU - Sperling B AU - Takeshima T PY - 2025 JO - Cephalalgia : an international journal of headache DO - 10.1177/03331024251386095 UR - https://doi.org/10.1177/03331024251386095 ER -
APA
S, Y., Y, M., BK, K., A, G., G, G., P, P., M, K. J., K, R., A, E., A, M., B, S., & T, T. (2025). Efficacy and safety of eptinezumab in a predominantly Asian population with chronic migraine: Results of the randomized, double-blind, placebo-controlled SUNRISE trial.. Cephalalgia : an international journal of headache. https://doi.org/10.1177/03331024251386095
Source records
- pubmed · retrieved 2026-09-27T01:10:40.583Z